Medvest
Medvest is an investment firm based in London, UK, with representatives in Tel-Aviv, Israel. The firm focuses on funding healthcare, digital health, and medtech projects, primarily targeting opportunities in the early stages of development, including those approaching pre-phase III clinical trials. Medvest partners with professional teams and entrepreneurs, guiding them through the commercialization process. The firm is supported by four partners and a professional consulting team known for its expertise in identifying and financing projects with capital requirements between $100,000 and $1.5 million. Medvest aims to expand its investment portfolio by attracting progressive investors interested in fostering innovation within the biotech and medical sectors. By employing a hands-on management approach, Medvest strives to transform promising projects into successful ventures.
Top Stages
1 past transactions
Providence Medical Technology
Venture Round in 2018
Providence Medical Technology, Inc. is a medical device company specializing in innovative solutions for cervical spine conditions, operating in the United States and internationally. The company has developed a proprietary approach to cervical fusion, offering a range of products designed to treat cervical degenerative disc disease through indirect decompression and fusion. Its product lineup includes the DTRAX Spinal System, which comprises single-use disposable instruments for accessing the spine via posterior surgical incisions; the DTRAX Cervical Cage for treating cervical radiculopathy; the DTRAX Graft, a structural allograft for supporting posterior fusion; and the DTRAX Facet System, a sterile kit containing necessary tools and implants for single-level surgeries. Providence Medical Technology distributes its products through a network of distributors and sales representatives and is headquartered in Lafayette, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.